The stock of DexCom Inc. (NASDAQ:DXCM) increased by $0.71 on Tuesday to $116.47, up 0.61 percent. The last five days have seen an average of 3,007,866 shares of common stock traded. 21 times new highs were reached in the current year, with a gain of $3.46. The average number of shares traded over the last 20 days was 3,566,846, while the average volume over the last 50 days totaled 2,958,707.
DXCM stock dropped -15.26% since last month. On 08/08/23, the company’s shares reached a one-month low of $107.07. The stock touched a high of $139.55 on 07/28/23, after rallying from a low of $78.94 in 52 weeks. The price of DXCM stock has risen by 2.85% or $3.46 this year, reaching a new high 21 times. Still, the stock price is down -16.54% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
DXCM stock investors should be aware that DexCom Inc. (DXCM) stock had its last reported insider trading activity 6 days ago on Aug 09. On Aug 09, EVP Chief Human Resources Offi Stern Sadie sold 392 shares at $110.71 each. This transaction resulted in the insider making $43,398. On Jul 24, Pacelli Steven Robert sold 412 shares at a price of US$130.58. After the transaction, the insider now owns 126,419 shares. EVP Managing Director Dexcom V Pacelli Steven Robert had earlier sold 5,031 shares on Jul 14 for $136.00 a share. The transaction was completed for $684,216.
Valuation Metrics
DexCom Inc. (DXCM) has a trailing price-to-earnings (P/E) ratio of 138.99. Beta for the stock is 1.10. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 14.33, the price-to-book (PB) ratio of 21.45, and the price-to-cash flow ratio of 98.31.
Financial Health
For the three months ended June 29, DexCom Inc.’s quick ratio was 2.20, while its current ratio was 2.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.19, and the total debt to equity ratio is 1.55. As far as profitability goes, gross margin for the trailing twelve months is 64.40% percent. DexCom Inc.’s EBITDA margin for the year ended June 29 was 18.80%, whereas its operating margin stood at 14.00% for the same period. Based on annual data, it had gross profit of $1.88 billion and revenue of $2.91 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. DXCM’s return on assets (ROA) during the last 12 months has been 6.30%. There was a 8.20% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 17.30%.
Earnings Surprise
According to DexCom Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $871.3 million, while revenues rose by 20.1% to $741.5 million. It was predicted that DexCom Inc.’s quarterly earnings would be $0.34, but it ended up being $0.23, beating the consensus by 47.80%. EBITDA was $171.8 million for the quarter. At the end of DexCom Inc.’s most recent quarter ended June 29, its liabilities totaled 4.72 billion, while its total debt was $3.37 billion. Equity owned by shareholders amounts to $387.87 million.
Technical Picture
Here’s a quick look at DexCom Inc.’s (DXCM) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 42.27%, suggesting the stock is Neutral, with a 54.66% historical volatility rate.
The stochastic %K and %D were 23.54% and 19.55% respectively, while the average true range (ATR) was 4.52. Based on the 14-day stochastic reading of 29.65%, the RSI (14) reading is 41.42%. On the 9-day MACD Oscillator, the stock is at -1.05, and the 14-day reading is at -4.86.
Analyst Ratings
Analysts have assigned DexCom Inc. (DXCM) an Buy rating. DXCM is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 4 rates it overweight and 17 others recommend it as a buy.
What is DXCM’s price target for the next 12 months?
The current consensus forecast for the stock is between $131.00 and $175.00, with a median target price of $150.00. In analyzing these forecasts, the average price target given by analysts for DexCom Inc. (DXCM) is $150.88.
